Browse > Article

Parkin Reduces Expression of Monocyte Chemotactic Protein-1 (MCP-1) in TNF-${\alpha}$-stimulated MCF7 Breast Cancer Cells  

Lee, Kyung-Hong (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Lee, Min-Ho (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Lee, In-Soo (Department of Clinical Laboratory Science, Hyejeon College)
Rhee, Ki-Jong (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Kim, Yoon-Suk (Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University)
Publication Information
Biomedical Science Letters / v.17, no.3, 2011 , pp. 261-265 More about this Journal
Abstract
Parkin is a putative tumor suppressor protein and its expression is frequently reduced or absent in several types of tumors. In this study, we examined the role of Parkin in mRNA expression of monocyte chemotactic protein-1 (MCP-1) in the breast cancer cell line MCF7. Expression of MCP-1 mRNA increased after TNF-${\alpha}$ treatment. However, overexpression of Parkin induced a decrease in expression of MCP-1 mRNA in TNF-${\alpha}$-stimulated MCF7. This decrease in MCP-1 mRNA by Parkin overexpression occurred in a dose- and time-dependent manner. Using a wound scratch assay, we found that Parkin overexpression in MCF7 cells also resulted in a decrease in cell migration. These results suggest that Parkin down-regulates MCP-1 synthesis leading to decreased migration of tumor cells. We suggest that one possible mechanism by which Parkin acts as a tumor suppressor is by inhibiting migration or metastasis of cancer cells.
Keywords
Parkin; MCP-1; Tumor suppressor; Cell migration;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Poulogiannis G, McIntyre RE, Dimitriadi M, Apps JR, Wilson CH, Ichimura K, Luo F, Cantley LC, Wyllie AH, Adams DJ, Arends MJ. PARK2 deletions occur frequently in sporadic colorectal cancer and accelerate adenoma development in Apc mutant mice. Proc Natl Acad Sci U S A. 2010. 107: 15145-15150.   DOI   ScienceOn
2 Shimura H, Schlossmacher MG, Hattori N, Frosch MP, Trockenbacher A, Schneider R, Mizuno Y, Kosik KS, Selkoe DJ. Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease. Science. 2001. 293: 263-269.   DOI
3 Soria, G, Ben-Baruch A. The inflammatory chemokines CCL2 and CCL5 in breast cancer. Cancer Lett. 2008. 267: 271-285.   DOI   ScienceOn
4 Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T, Weitzenfeld P, Meshel T, Shabtai E, Gutman M, Ben-Baruch A. Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer. 2011. 11: 130.   DOI
5 Tay SP, Yeo CW, Chai C, Chua PJ, Tan HM, Ang AX, Yip DL, Sung JX, Tan PH, Bay BH, Wong SH, Tang C, Tan JM, Lim KL. Parkin enhances the expression of cyclin-dependent kinase 6 and negatively regulates the proliferation of breast cancer cells. J Biol Chem. 2010. 285: 29231-29238.   DOI
6 Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 2010. 42: 77-82.   DOI   ScienceOn
7 Wang F, Denison S, Lai JP, Philips LA, Montoya D, Kock N, Schule B, Klein C, Shridhar V, Roberts LR, Smith DI. Parkin gene alterations in hepatocellular carcinoma. Genes Chromosomes Cancer. 2004. 40: 85-96.   DOI   ScienceOn
8 Yin Y, Chen X, Shu Y. Gene expression of the invasive phenotype of TNF-alpha-treated MCF-7 cells. Biomed Pharmacother. 2009. 63: 421-428.   DOI
9 Balkwill, F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev. 2006. 25: 409-416.   DOI   ScienceOn
10 Ciechanover A. Linking ubiquitin, parkin and synphilin-1. Nat Med. 2001. 7: 1108-1109.   DOI   ScienceOn
11 Conti I, Rollins BJ. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin Cancer Biol. 2004. 14: 149-154.   DOI   ScienceOn
12 Denison SR, Wang F, Becker NA, Schule B, Kock N, Phillips LA, Klein C, Smith DI. Alterations in the common fragile site gene Parkin in ovarian and other cancers. Oncogene. 2003. 22: 8370-8378.   DOI   ScienceOn
13 Kitada T, Asakawa S, Hattori N, Matsumine H, Yamamura Y, Minoshima S, Yokochi M, Mizuno Y, Shimizu N. Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism. Nature. 1998. 392: 605-608.   DOI   ScienceOn
14 Lu T, Stark GR. Cytokine overexpression and constitutive NFkappaB in cancer. Cell Cycle. 2004. 3: 1114-1117.
15 Mochizuki Y, Nakanishi H, Kodera Y, Ito S, Yamamura Y, Kato T, Hibi K, Akiyama S, Nakao A, Tatematsu M. TNF-alpha promotes progression of peritoneal metastasis as demonstrated using a green fluorescence protein (GFP)-tagged human gastric cancer cell line. Clin Exp Metastasis. 2004. 21: 39-47.   DOI
16 Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM. Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells. Cancer Res. 2006. 66: 7176-7184.   DOI   ScienceOn
17 Neumark E, Sagi-Assif O, Shalmon B, Ben-Baruch A, Witz IP. Progression of mouse mammary tumors: MCP-1-TNFalpha cross-regulatory pathway and clonal expression of promalignancy and antimalignancy factors. Int J Cancer 2003. 106: 879-886.   DOI   ScienceOn
18 Picchio MC, Martin ES, Cesari R, Calin GA, Yendamuri S, Kuroki T, Pentimalli F, Sarti M, Yoder K, Kaiser LR, Fishel R, Croce CM. Alterations of the tumor suppressor gene Parkin in non-small cell lung cancer. Clin Cancer Res. 2004. 10: 2720-2724.   DOI   ScienceOn
19 Anderson GM, Nakada MT, DeWitte M. Tumor necrosis factoralpha in the pathogenesis and treatment of cancer. Curr Opin Pharmacol. 2004. 4: 314-320.   DOI   ScienceOn